Oral Semaglutide – Medxy AI

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

By MedXY 09/17/2025

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Clinical Updates Wellness & Lifestyle

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial

By MedXY 09/08/2025

The OASIS 2 trial shows oral semaglutide 50 mg significantly reduces body weight in East Asian adults with overweight or obesity, with or without type 2 diabetes, offering a promising therapeutic option with manageable safety profile.

Clinical Updates Wellness & Lifestyle

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY 08/17/2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.